老虎证券

BUZZ-Keros Therapeutics plunges as dosing halted in trial due to safety concerns

Reuters
2024/12/12
BUZZ-Keros <a href="https://laohu8.com/S/LENZ">Therapeutics</a> plunges as dosing halted in trial due to safety concerns

** Shares of drug developer Keros Therapeutics KROS.O fall ~71% to $20 premarket

** KROS says it has halted dosing of 3.0 mg and 4.5 mg doses of its high blood pressure treatment in a mid-stage study due to fluid buildup around the heart

** Dosing in the 1.5 mg/kg arm will continue after a risk-benefit review by an independent monitoring committee - KROS

** Co has notified the U.S. FDA about it and expects to present data from all treatment arms in Q2 2025 - KROS

** As of last close, stock has fallen 25.7% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10